Work

Эффективность супрессивной терапии каберголином у больных молодого возраста с пролактиномой

Year: 2016
Type: article
Abstract: The aim — to study the clinical and hormonal features of PROL (prolactinoma), manifesting in people under the age of 18 y. o. and to evaluate the effectiveness of suppressive CAB (Cabergoline, Dostinex) therapy during 12 months period.Materials and methods. The study included 11 patients with PROL, manifesting in childhood. The clinical examination included: medical history, anthropometry, evaluation of physical and pubertal development (Tanner stage), blood pressure measurement, objective examination (including consultations of ophthalmologist, neurologist, cardiologist, gynecologist etc). Blood samples for PRL (prolactin), GH (Growth hormone), IGF­­1 (insulin­­like growth factor­­1), LH (luteinizing hormone), FSH (follicle stimulating hormone), T (total testosterone), E2 (estradiol), TSH (thyrotropin), fT4 (free thyroxine), cortisol were taken fasting. There were also examined 54 healthy volunteers (25 males and 29 females) aged 15—19 y. o. to determine the range of normal PRL blood values. Pituitary adenoma was verified by MRI. Microadenoma diagnosed in case of pituitary tumor diameter ≤ 10 mm; macroadenoma — 11—30 mm and giant adenoma > 30 mm. Pituitary volume (cm3) was calculated according to Di­­Chiro­­Nelson formula, using the correction coefficient as 1.33. We evaluated total secretory activity (TSA, ng/ml), partial secretory activity (PaSA, ng/ml/cm3) and the speed of tumor growth (SpTG, cm3/yr) by V. Pronin. Target PRL levels in patients receiving suppressive therapy with CAB corresponded to 5th percentile.Results and discussion. Normal values of the PRL blood levels in healthy children of both sex aged 15—19 y. o. were determined and percentile diagrams were plotted. Among the 11 patients with PROL diagnosed in childhood (Me = 16.0 yrs) [Min. 12.0 — Max. 18.0] there were 9 girls and 2 boys. MikroPROL was diagnosed in 7 girls (average age of manifestation: ME = 17.5 yrs), makroPROL had 4 patients (2 girls and 2 boys) (average age of manifestation: ME = 16.0 yrs), among them 1 girl and 1 boy (12 and 16 years old accordingly) had a gigantic PROL. Neurological symptoms were observed in 11 patients (100 %); 7 had moderate hypotension, 8 girls in late puberty had menstrual disorders (opsomenorrhea and secondary amenorrhea); galactorrhea of II stage was found in 3 girls and 2 boys; 3 children had delay of growth and puberty. At primary examination a level of PRL was (174.8 ± 49.4) ng/ml (Me = 89.6 ng/ml) [Min. 27.6 — Max. 470.0]: macroPROL — Me = 52.3 ng/ml [Min. 27.6 — Max. 470.0]; microPROL — Me = 200.0 ng/ml [Min. 46.4 — Max. 480.0]. Before treatment PaSA was Me 81.3 ng/ml/cm3 [Min. 6.2 — Max. 783.0] (in group with macro­ and giant PROL Me = 47.1 ng/ml/cm3 [Min. 6.2 — Max. 90.8]; with microPROL — Me = 98.9 ng/ml/cm3 [Min. 45.3 ­ Max. 783.3] (p < 0,05). SpTG was 0.8 cm3/yr [Min. 0.2 — Max. 32.0]. Univariate regression analysis showed that the average therapeutic CAB dose was: Me = 1.0 mg/week [Min. 0.2 — Max. 2.0] mg/week; the average cumulative dose — Me = 44.2 mg/yr [Min. 12 — Max. 104.0] mg/yr. It was found a statistically significant decrease of PRL level after 1 month of therapy, but the most positive effect was achieved after 3 months therapy (n = 9). The high efficiency of high start doses of CAB was confirmed by MRI: after 12 months of therapy the decreasing of the pituitary volume by 50 % or more was marked in 5 patients, in 2 patients — by 30—49 %, and 2 girls became pregnant.Conclusions. It was found that clinical and hormonal features of PROL in patients under the age of 18 y.o. are the rapid tumor growth and formation of a macro­ and giant adenoma in a short term. Prescription of high start doses of CAB is a safe and effective in treatment of PROL in children, as evidenced by the absence of side effects, the normalization of the pituitary­­gonadal axis and growth hormone function, rapid sustained reduction of PRL level to 5th percentile in most patients (90.1 %), statistically significant reduction of PaSA in all patients, decrease of pituitary tumor by 50 % or more — in 54.5 % patients.
Language: Russian
Field: Medicine
Open Access status: green
OpenAlex ID: W3042884029
FWCI:
Cites: 26
Cited by:
Related to: 8